Abstract
Lipopolysaccharide (LPS), the Gram-negative bacterial outer membrane glycolipid, induces sepsis through its interaction with myeloid differentiation protein-2 (MD-2) and Toll-like receptor 4 (TLR4). To block interaction between LPS/MD-2 complex and TLR4, we designed and generated soluble fusion proteins capable of binding MD-2, dubbed TLR4 decoy receptor (TOY) using ‘the Hybrid leucine-rich repeats (LRR) technique’. TOY contains the MD-2 binding ectodomain of TLR4, the LRR motif of hagfish variable lymphocyte receptor (VLR), and the Fc domain of IgG1 to make it soluble, productive, and functional. TOY exhibited strong binding to MD-2, but not to the extracellular matrix (ECM), resulting in a favorable pharmacokinetic profile in vivo. TOY significantly extended the lifespan, when administered in either preventive or therapeutic manners, in both the LPS- and cecal ligation/puncture-induced sepsis models in mice. TOY markedly attenuated LPS-triggered NF-κB activation, secretion of proinflammatory cytokines, and thrombus formation in multiple organs. Taken together, the targeting strategy for sequestration of LPS/MD-2 complex using the decoy receptor TOY is effective in treating LPS- and bacteria-induced sepsis; furthermore, the strategy used in TOY development can be applied to the generation of other novel decoy receptor proteins.
Highlights
Sepsis caused by Gram-negative bacterial infection is a lifethreatening disease characterized by profound inflammatory responses, multi-organ dysfunction with marked thrombus formation, and a high mortality rate (,60%) [1]
We produced a fusion of IgG-Fc to the Toll-like receptor 4 (TLR4) full-length ectodomain (TFE; Figure 1A)
In vitro binding analysis revealed that TFE, TOY3, or TOY8 could interact with myeloid differentiation protein-2 (MD-2) and with LPS/MD-2 complex (Figure 2 and Figure S1)
Summary
Sepsis caused by Gram-negative bacterial infection is a lifethreatening disease characterized by profound inflammatory responses, multi-organ dysfunction with marked thrombus formation, and a high mortality rate (,60%) [1]. In this regard, blocking TLR4 signaling activation using a decoy receptor could be an effective way to prevent LPS- or Gramnegative bacteria-induced sepsis if applied prior to or after challenge. By fusion of the Fc domain of IgG1 to TV3 and TV8, we were able to generate dimeric TLR4 decoy receptor TOY, which is effective in treating LPS- and bacteria-induced sepsis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.